Aralez Pharmaceuticals (ARLZ) announced that it has acquired rights to Merck's (MRK) antiplatelet drug ZONTIVITY (vorapaxar) in the U.S. and Canada. Under the terms of the asset purchase agreement, Merck will receive an upfront cash payment of $25 million plus sales-based milestones and royalties. Merck will continue to distribute the product for up to 12 months on Aralez's behalf while the product rights, packaging, labeling and other items are transferred to Aralez's Ireland-based subsidiary Aralez Pharmaceuticals Trading DAC.